Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors

BACKGROUND: ALK fusions are targetable drivers in non-small-cell lung cancer (NSCLC). However, patients with NSCLC harboring ALK rearrangements without a fusion partner identified in DNA have also been shown to respond to ALK inhibitors. We aimed to characterize complex ALK variants that may predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Schrock, Alexa B, Madison, Russell, Rosenzweig, Mark, Allen, Justin M, Erlich, Rachel L, Wang, Siao-Yi, Chidiac, Tarek, Reddy, Vodur Suresh, Riess, Jonathan W, Yassa, Ahmet Ersin, Shakir, Abdur, Miller, Vincent A, Alexander, Brian M, Venstrom, Jeffrey, McGregor, Kimberly, Ali, Siraj M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184117/
https://www.ncbi.nlm.nih.gov/pubmed/32368168
http://dx.doi.org/10.2147/LCTT.S239675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184117/
https://www.ncbi.nlm.nih.gov/pubmed/32368168
http://dx.doi.org/10.2147/LCTT.S239675

Ejemplares similares